Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus

Journal of Diabetes Investigation

Volumn 7, Issue , 2016, Pages 56-63

  Knudsen, Lotte Bjerre ^a   Secher, Anna ^a   Hecksher Sørensen, Jacob ^a   Pyke, Charles ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Arcuate nucleus; Liraglutide; Obesity

Indexed keywords

AGOUTI RELATED PROTEIN; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MESSENGER RNA; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; NERVE PROTEIN;

APPETITE; ARCUATE NUCLEUS; AREA POSTREMA; ARTICLE; ENERGY EXPENDITURE; HUMAN; HUNGER; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS; MEDIAN EMINENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; SATIETY; STOMACH DISTENSION; STOMACH EMPTYING; WEIGHT REDUCTION; AGONISTS; ANIMAL; BRAIN; DRUG EFFECTS; METABOLISM; MOUSE; NERVE CELL; PANCREAS;

ANIMALS; BRAIN; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOTHALAMUS; LIRAGLUTIDE; MICE; NERVE TISSUE PROTEINS; NEURONS; PANCREAS; PRO-OPIOMELANOCORTIN;

EID: 84963490983     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12463     Document Type: Article

References (47)

1. Bell GI, Santerre RF, Mullenbach GT. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 1983; 302: 716-718.
2. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987; 79: 616-619.
3. Holst JJ, Orskov C, Nielsen OV, et al. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-174.
4. Vilsboll T, Krarup T, Madsbad S, et al. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 2002; 45: 1111-1119.
5. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
6. Tang-Christensen M, Larsen PJ, Göke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848-R856.
7. Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520.
8. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 1664-1669.
9. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014; 4: 289-297.
10. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet 2014; 384: 1349-1357.
11. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
12. Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 2014; 124: 4473-4488.
13. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273: E981-E988.
14. Ruttimann EB, Arnold M, Hillebrand JJ, et al. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009; 150: 1174-1181.
15. Hayes MR, Bradley L, Grill HJ. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 2009; 150: 2654-2659.
16. Labouesse MA, Stadlbauer U, Weber E, et al. Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. J Neuroendocrinol 2012; 24: 1505-1516.
17. Nauck MA, Kemmeries G, Holst JJ, et al. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes 2011; 60: 1561-1565.
18. Jelsing J, Vrang N, Hansen G, et al. Liraglutide: short-lived effect on gastric emptying/long lasting effects on body weight. Diabetes Obes Metab 2012; 14: 531-538.
19. van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite, and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 784-793.
20. Vrang N, Larsen PJ. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog Neurobiol 2010; 92: 442-462.
21. Barrera JG, Jones KR, Herman JP, et al. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 2011; 31: 3904-3913.
22. Sisley S, Gutierrez-Aguilar R, Scott M, et al. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. J Clin Invest 2014; 124: 2456-2463.
23. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology 2012; 153: 647-658.
24. Mietlicki-Baase EG, Ortinski PI, Reiner DJ, et al. Glucagon-like peptide-1 receptor activation in the nucleus accumbens core suppresses feeding by increasing glutamatergic AMPA/kainate signaling. J Neurosci 2014; 34: 6985-6992.
25. Alhadeff AL, Baird JP, Swick JC, et al. Glucagon-like peptide-1 receptor signaling in the lateral parabrachial nucleus contributes to the control of food intake and motivation to feed. Neuropsychopharmacology 2014; 39: 2233-2243.
26. Plamboeck A, Veedfald S, Deacon CF, et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol 2013; 304: G1117-G1127.
27. Kristensen P, Judge ME, Thim L, et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393: 72-76.
28. Schwartz MW, Woods SC, Porte D, et al. Central nervous system control of food intake. Nature 2000; 404: 661-671.
29. Woods SC, Schwartz MW, Baskin DG, et al. Food intake and the regulation of body weight. Annu Rev Psychol 2000; 51: 255-277.
30. Luquet S, Perez FA, Hnasko TS, et al. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 2005; 310: 683-685.
31. Cansell C, Denis RG, Joly-Amado A, et al. Arcuate AgRP neurons and the regulation of energy balance. Front Endocrinol (Lausanne) 2012; 3: 169 doi: 10.3389/fendo.2012.00169. eCollection 2012.
32. Balland E, Dam J, Langlet F, et al. Hypothalamic tanycytes are an ERK-gated conduit for leptin into the brain. Cell Metab 2014; 19: 293-301.
33. Hileman SM, Pierroz DD, Masuzaki H, et al. Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity. Endocrinology 2002; 143: 775-783.
34. Schaeffer M, Langlet F, Lafont C, et al. Rapid sensing of circulating ghrelin by hypothalamic appetite-modifying neurons. Proc Natl Acad Sci USA 2013; 110: 1512-1517.
35. Heppner KM, Kirigiti M, Secher A, et al. Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. Endocrinology 2015; 156: 255-267.
36. Raun K, von Voss P, Gotfredsen CF, et al. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007; 56: 8-15.
37. Hansen G, Jelsing J, Vrang N. Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats. Acta Pharmacol Sin 2012; 33: 194-200.
38. Erreger K, Davis AR, Poe AM, et al. Exendin-4 decreases amphetamine-induced locomotor activity. Physiol Behav 2012; 106: 574-578.
39. Lean ME, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 689-697.
40. Van Bloemendaal L, IJzerman RG, Ten Kulve JS, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 2014; 63: 4186-4196.
41. van Bloemendaal L, Veltman DJ, Ten Kulve JS, et al. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by GLP-1 receptor activation in humans. Diabetes Obes Metab 2015; 17: 878-886.
42. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7-14.
43. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci 2012; 13: 33. doi:10.1186/1471-2202-13-33.
44. Abernethy WB, Bell MA, Morris M, et al. Microvascular density of the human paraventricular nucleus decreases with aging but not hypertension. Exp Neurol 1993; 121: 270-274.
45. Ciofi P. The arcuate nucleus as a circumventricular organ in the mouse. Neurosci Lett 2011; 487: 187-190.
46. Langlet F, Mullier A, Bouret SG, et al. Tanycyte-like cells form a blood-cerebrospinal fluid barrier in the circumventricular organs of the mouse brain. J Comp Neurol 2013; 521: 3389-3405.
47. Christensen M, Sparre-Ulrich AH, Hartmann B, et al. Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. Int J Obes (Lond) 2015; 39: 1651-1654.